Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance)

Journal of Clinical Oncology

Volumn 32, Issue 10, 2014, Pages 997-1005

  Loprinzi, Charles L ^a   Qin, Rui ^a   Dakhil, Shaker R ^b   Fehrenbacher, Louis ^c   Flynn, Kathleen A ^d   Atherton, Pamela ^a   Seisler, Drew ^a   Qamar, Rubina ^e   Lewis, Grant C ^f   Grothey, Axel ^a  

^a MAYO CLINIC   (United States)

^b WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^c Louis Fehrenbacher Kaiser Permanente Vallejo   (United States)

^d Michigan Cancer Research Consortium   (United States)

^e Rubina Qamar Aurora Cancer Care Milwaukee West   (United States)

^f Summit Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GLUCONATE CALCIUM; MAGNESIUM SULFATE; OXALIPLATIN; PLACEBO; ANTINEOPLASTIC AGENT; CALCIUM; MAGNESIUM; PLATINUM COMPLEX;

ABDOMINAL CRAMP; ABNORMAL LABORATORY RESULT; ADJUVANT THERAPY; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL ASSESSMENT TOOL; COLON CANCER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DYSPHAGIA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INTESTINAL DYSMOTILITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NATIONAL HEALTH ORGANIZATION; NCI CTCAE THE GRADING SCALE; NEUROPROTECTION; NEUROTOXICITY; PARALLEL DESIGN; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QLQ CIPN20 SCORE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; CHEMICALLY INDUCED DISORDER; COLD; COLON TUMOR; CONTROLLED CLINICAL TRIAL; INTRAVENOUS ADMINISTRATION; MIDDLE AGED; SENSORY DYSFUNCTION;

ADMINISTRATION, INTRAVENOUS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCIUM; COLD TEMPERATURE; COLONIC NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MAGNESIUM; MALE; MIDDLE AGED; MUSCLE CRAMP; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; SENSATION DISORDERS;

EID: 84901675767     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.0536     Document Type: Article

References (19)

1. Grothey A, Nikcevich DA, Sloan JA, et al: Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 29:421-427, 2011
2. Gamelin L, Boisdron-Celle M, Delva R, et al: Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055-4061, 2004 (Pubitemid 38812481)
3. Hochster HS, Grothey A, Childs BH: Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 25:4028-4029, 2007 (Pubitemid 47477294)
4. Gamelin L, Boisdron-Celle M, Morel A, et al: Oxaliplatin-related neurotoxicity: Interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 26:1188-1189, 2008
5. Grothey A, Hart LL, Rowland KM, et al: Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial. J Clin Oncol 26:180s, 2008 (suppl; abstr 4010)
6. André T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004 (Pubitemid 38702845)
7. Postma TJ, Aaronson NK, Heimans JJ, et al: The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. Eur J Cancer 41:1135-1139, 2005 (Pubitemid 40725571)
8. Lévi FA, Zidani R, Vannetzel JM, et al: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multiinstitutional trial. J Natl Cancer Inst 86:1608-1617, 1994 (Pubitemid 24336347)
9. Lavoie Smith EM, Barton DL, Qin R, et al: Assessing patient-reported peripheral neuropathy: The reliability and validity of the European Organization for Research and Treatment of Cancer QLQCIPN20 Questionnaire. Qual Life Res [epub ahead of print on March 30, 2013]
10. Barton DL, Wos EJ, Qin R, et al: A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 19:833-841, 2011
11. Puttabasavaiah S, Liu H, Qin R, et al: A comparison of simple single-item measures and the NCI Common Toxicity Criteria version 3.0 measure of peripheral neuropathy. J Clin Oncol 30:99s, 2012 (suppl; abstr 1557)
12. Knijn N, Tol J, Koopman M, et al: The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer 47:369-374, 2011
13. Kono T, Mamiya N, Chisato N, et al: Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer. Evid Based Complement Alternat Med 2011:418481, 2011
14. Chay WY, Tan SH, Lo YL, et al: Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. Asia Pac J Clin Oncol 6:270-277, 2010
15. Ishibashi K, Okada N, Miyazaki T, et al: Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: A prospective randomized study. Int J Clin Oncol 15:82-87, 2010
16. Dong M, Xing PY, Liu P, et al: Assessment of the protective effect of calcium-magnesium infusion and glutathione on oxaliplatin-induced neurotoxicity [in Chinese]. Zhonghua Zhong Liu Za Zhi 32:208-211, 2010
17. Wolters Kluwer Health: UpToDate. http://www.uptodate.com
18. Durand JP, Deplanque G, Montheil V, et al: Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: Results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 23:200-205, 2012
19. Smith EM, Pang H, Cirrincione C, et al: Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial. JAMA 309:1359-1367, 2013